Prostate Cancer Lymphangitic Pulmonary Carcinomatosis: Appearance on 18F-FDG PET/CT and 18F-DCFPyL PET/CT.

A 51-year-old man diagnosed with high-grade, high-volume metastatic castration-sensitive prostate adenocarcinoma received pelvic radiation, androgen deprivation therapy, and intravenous docetaxel. Serum prostate-specific antigen became undetectable following treatment. Within a year, his cancer progressed to castration-resistant disease, and he was treated with oral abiraterone acetate 1000 mg and prednisone 10 mg daily. Despite this, the serum prostate-specific antigen rose from 0.03 to 1.39 μg/L, and F-DCFPyL and F-FDG PET/CT showed progression. While F-DCFPyL uptake may be seen in aggressive disease, F-FDG portends poor prognosis. Despite intravenous platinum-based chemotherapy, the patient died of respiratory failure 20 months after his initial diagnosis.

Clinical nuclear medicine. 2020 Jun 08 [Epub ahead of print]

Katherine A Zukotynski, Hossein Jadvar, Kylea Potvin, Steve Y Cho, Chun Ki Kim, Eric Winquist

From the Departments of Medicine and Radiology, McMaster University, Hamilton, Ontario, Canada., Department of Radiology, University of Southern California, Los Angeles, CA., Department of Oncology, Western University, London, Ontario, Canada., Department of Radiology, University of Wisconsin, Madison, WI., Department of Medicine, Hanyang University College of Medicine, Seoul, Korea.